10. Treatment comparison to control: serious infections ‐ network meta‐analysis MTC.

OR RE Model	Standard Dose Model Median (95% CI)
Abatacept	0.97 (0.40 to 2.31)
Adalimumab	1.23 (0.65 to 2.40)
Anakinra	4.05 (1.22 to 16.84)*
Certolizumab	4.75 (1.52 to 18.45)*
Etanercept	1.29 (0.72 to 2.45)
Golimumab	1.11 (0.45 to 2.59)
Infliximab	1.41 (0.75 to 2.62)
Rituximab	0.26 (0.03 to 2.16)
Tocilizumab	0.84 (0.20 to 3.56)
Overall	1.37 (1.04, 1.82)*
Data points Residual deviance DIC	(115) 123.2 494.12

* = statistically significant; OR = odds ratio; RE model = random‐effects model; 95% CI = 95% credible interval; DIC = Deviance information criteria